Albireo, an Ipsen Company
Clinical trials sponsored by Albireo, an Ipsen Company, explained in plain language.
A biopharmaceutical company focused on liver diseases, now part of Ipsen.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug may help kids with rare liver disease avoid transplant Results expected Oct 2026 (estimated)
- New hope for kids with rare liver disease: long-term drug study launched Results expected Dec 2026 (estimated)
-
Promising long-term results for rare liver disease drug in kids
Disease control CompletedThis study looked at the long-term safety and effectiveness of a drug called A4250 (odevixibat) in 116 children with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. The children took the drug for up to 72 weeks. The study measured changes in bile acid …
Phase 3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could this pill help kids with biliary atresia skip a liver transplant?
Disease control CompletedThis Phase 3 study tests odevixibat, a daily pill, in 254 children with biliary atresia who recently had Kasai surgery. The goal is to see if the drug can prevent the need for a liver transplant or death. Children take either odevixibat or a placebo for up to 2 years, and researc…
Phase 3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC